<SEC-DOCUMENT>0001144204-11-033046.txt : 20110531
<SEC-HEADER>0001144204-11-033046.hdr.sgml : 20110530
<ACCEPTANCE-DATETIME>20110531061643
ACCESSION NUMBER:		0001144204-11-033046
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110531
FILED AS OF DATE:		20110531
DATE AS OF CHANGE:		20110531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		11879626

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v224557_6k.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="72%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 6-K</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report of Foreign Private Issuer</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the Securities Exchange Act of 1934</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the month of May, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">XTL Biopharmaceuticals Ltd.</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="40%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation of registrant&#8217;s name into English)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">85 Medinat Hayehudim St., Herzliya</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pituach, PO Box 4033,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Herzliya 46140, Israel</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<hr style="COLOR: black" align="center" noshade size="1" width="40%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Form 20-F</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">Form 40-F</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Yes</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">No</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;N/A&#160;&#160; </font></font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="72%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;&#160;</div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated May 31, 2011 is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL Biopharmaceuticals (the "Company") Announces</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Receipt of Orphan-drug Designation in the United States for</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Company's Drug Treatment for Multiple Myeloma</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached&#160;hereto is an English translation (from Hebrew) of an announcement that XTL Biopharmaceuticals Ltd. has received Orphan-drug designation in the United States for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Company's Drug Treatment for Multiple Myeloma.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;&#160; </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="logo.jpg"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">XTL Biopharmaceuticals Ltd</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">("the Company")</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">May 29, 2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear Sirs,</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re:&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-DECORATION: underline">Immediate Report</font></font></font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RE:<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-DECORATION: underline">Receipt of Orphan-drug Designation in the United States (US) for the </font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-DECORATION: underline">Company's drug treatment for Multiple Myeloma</font></font></font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further to the Company's announcement on April 21<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>, 2011, regarding its application for an Orphan-drug designation for its recombinant human erythropoietin (rHuEPO) drug, the Company hereby announces that on Sunday, May 29<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2011, it was notified that its EPO drug (currently in preparations for phase 2 clinical trial) has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An orphan drug is defined as a drug treatment for an illness that affects a relatively small number of people in the population. In the US, an orphan drug designation is limited in connection with illnesses that affects less than 200,000 people a year.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to encourage the development of treatments to these diseases, regulatory authorities provide benefits and incentives for the developers. The standard benefit available for orphan drugs in the US is the right of sole exclusivity of marketing the drug for a period of seven (7) years from the day of FDA approval. Additional benefits include local tax credit in the US on research and development expenses, and exemption from payment of commissions to the FDA, a sub-unit of the US Department of Health &amp; Human Services.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Respectfully;</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XTL Biopharmaceuticals Ltd.</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">XTL Biopharmaceuticals Ltd.&#160;85 Medinat Hayehudim St., Herzliya Pituach 46766, Israel Tel:&#160;+972-9-955-7080&#160;Fax:&#160;+972-9-951-9727</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160; <br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor Relations, XTL Biopharmaceuticals Ltd.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +972 9 955 7080, Email: ir@xtlbio.com</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary Statement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of the statements included in this Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></div>

&#160;<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="46%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XTL BIOPHARMACEUTICALS LTD.</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="46%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: May 31, 2011</font></div>
</td>
<td valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="46%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ David Grossman</font></font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David Grossman</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="HDR">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M```L`0```0```"P!```!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`$8`
MI`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^*XWXB>//#?PM\`^-OB5XQO6T[PG\/O"/B3QOXGOUB>=K+P]X
M4T:\U[6KQ84P\S6NF6%S.(E(:3R]JD$YK\EO^"W?A+]LZ']E#4?CE^Q%\;/B
M3\,?B+\!4U/QCXS\'^!+V)(OB3\,#;1MXK!L)[2[$WB/P3!:1^*=(:V$<]UH
MUMXFTM(;Z_O=)BA_BV_9I_X+8_M@67QD\,:3^UY\??B3\<?V7_'$6M?#3X^?
M#?Q-=VMY:ZK\*_B/HU]X,\8ZAIT=EI]O?IK_`(=TC6KCQ#HBV=Q;R7FH:7#I
MDLJVM]<9_3.$_#+,^+LFQ&=Y9C\NK4\!5JT\=E4:N(AFZ=&*JJC1I_5IT'4Q
ME#7!U)5E2G4E[.<HSIU8P^"XCX\P?#F:4LIQN!QM.>+A2EA<P<:+P#55JFZM
M1^VC65/#56UB5&FYQA'GBFI1;_0CQ)_P=A?M5O\`&R;7O"GP$^"</P#@UQTL
M_A_KD7C"7XBZAX56Z8*VH_$&R\4)HUAXHGL\.MQ9^"+S1-.N'\E],UB.$W-Q
M_;K^SK\<_!W[3'P+^%'Q^^'YNU\'_%SP)X<\=Z';ZC&D6I:?;:_IL%[)I.IQ
M1O)%'JFCW3W&E:DD,LT"WUG<+!--$$D;^(2[_P"#5KX\^(OB38:Q\-/VG_@1
MK'[+'B.:T\1>'OB?J$OBR?XA?\*\U5(]2TV_'@S2_#;^$==U5M&N;>:VNK/X
MA:7HFKIF_6?1XYX["/XO_;`_X*Z_'KX6?%*P_9Y_X)[_`+0GC[X6?LD_LQ^#
M?#GP`^%,GA:_TU)?B9;?#R"73-<^+FOWC:=*+_4O'OB`ZEJEC<0+:6C^'QHT
MR:?97<UZC?I6><#<%\<O*<!X8?4L/C<%A9XC.<75>84L+A\$XPIX:EF;J4:L
MUFU?$\_LH*'MI4Z6+EB&HPHGP^5<6<3\*1Q^-XY>*Q&%Q5:-++L-%X.>(JXE
M2<ZU7!<E2%-8"E1<?:2<_9<]7#1HWE*H?Z65%?R8_LG>*?\`@HYX2_X(Y_M?
M?MU_M(_M/_&+5_B=XX^!7B7Q=^SCH^N:I:QS_#CP;H]E-=Z-\1X;9=.@4>(_
M'=VR:GHS7<5U#:>#K31;^T?=XDOX+?\`EQ_X?/?\%3/^CV?C9_X-],_II('Y
M`"OA\C\'<ZXBQ&=T,LSK(JT<BS%97BL1[7&_5ZV*5&G5J_59QP4I5*=&<Y4)
M3E""G5IS=/GIN-27U6:^)N6Y/0RNMC<IS:F\VP2Q]"CRX3VM*A*K4IT_;QEB
M8J,ZL8*K&,7*T)Q4^6?-%?ZKE%?Y49_X+/?\%3!U_;:^-@STSJ^F#_W$T?\`
M#YW_`(*F?]'L_&S_`,&^F?\`RIKZ'_B7;B[_`*&_#W_@_,/+_J7^OX=]/&_X
MC5D'_0JSC_P'!?\`S6?ZKE%?Y4?_``^>_P""I@Z_MM?&P?\`<7TS_P"5-?H]
M_P`$BO\`@J1_P4&^./\`P4=_99^%'Q:_:M^*OCOX=>,_&>OZ?XH\):[J=A-I
M.M65MX!\7:G!;WL46G0R/'%?V-I=*$E0B6",YP"#PYIX"\4Y5EF8YI7S3(JE
M#+<!B\PK0HUL<ZLZ6#P]3$U(4U/`PBZDH4Y*"E*,7)QO))MKKP'B_D>88[!8
M"GEN:PJ8W%X?"4YU(X/DA/$UH482GRXJ4N2,IIRY8RE9.R;T/]#ZBD7.U<\G
M`R??%+7X:G=)]TG]Y^LA17\X?BG]JK]HFR_X+`6?P+M/BWXN@^$<GQ@\%:(_
M@-+R'^P6TC4?`VAZE>Z>8#;F3[/<7L\]PZB0$R2N<C(Q_1Y7W/&G`>9\$4>%
M*V98O`XJ/%W"^6\5X%8*6(D\/@LSBY4</B_;T*"6*II?O51=6BFURU9:V_-O
M#SQ-RCQ'K<:T<JP&98&7`_&.:\%YC+,(X:*Q>891*,:^*P7U;$8AO!U')>R=
M=4:S2?/1@%%%?+W[:-Y\5K#]F#XOWGP/'BAOBM!X<@;P4O@NSN+_`,3G5#K.
MEJXT>SM8+FXN+G[$UUE(H)&\D2MMP"1\KE>!>9YGEV61KX?"RS''X/`1Q6+G
M[/"X:6,Q%/#QQ&)J)-T\/1=15*TTFX4XRDD[6/MLZS..2Y-FV<2PN*QT<IRS
M'YG+!8&FJV-QD<!A:N*>%P=)N*JXK$*E['#TW**G6G"+:O<^H:*_*[_@E=K7
M[6NL?#?XER?M;Q_%6/Q3%XZLX_"R_%;1=1T34_\`A'O^$>LVG.EPZA86$DMA
M_:1F#RHCI]H,BEMRX7]4:]/BOA^?"O$.:</5,QRW-IY76A1EF.45Y8G+<4YT
M*5?GPE>4*<JM.*J^SE)PC:I"<;:7?C\$<54^-N%<GXIHY5FV1T\XH5*\,JSS
M#QPF:X-4\16P[IXS#1G45*I)T74C%3E>G.$OM6"BBBOGCZL****`(YH8KB*2
M">-)89D:*6*15>.2-P5>-T8%71U)5E8$,"01@U_F8_\`!=[_`()LR?L$?M8W
M_B/X>Z')9_LX?M`76L^-OA6UI`_]F^#=:%RD_C3X7&1%6.V3PU?WT&H^&;=@
M`?!^K:/:1S7EYI.K21_Z:5?C_P#\%U/A_P#LY>.O^":_Q_G_`&CM5@\.:7X-
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MRX@O_"JF7PG_`((E_P#!-C4/^"AG[5NE1^,='O'_`&<O@Q<:1XU^-FJ&.6*R
MUZ+[4\OAGX7VUXH4#4/'=]8SQ:B(98;BS\(Z?XCOK>X@U"/3([G\:*_TR?\`
M@W>/[-)_X)H_"T_L\C&L_P!J:N/V@O[2-JWBK_A?*BU'BG^WC;?*+`Z5_8)\
M#(/N^`#X9%P6U3^TF/\`1GB-7P_AKPKG6+X9P$\/C^+,WFL1CJ4;PP6)QE&4
MZ^+E)).D^2E5C@H)JE3Q>(=6*T=.?XGP70K<;\0Y5A\\QD:V$X?R^G['"U9+
MFQ5'"U8^RPZBW:IS2G!XJ=G.IAZ*A*^DH_MG)X9\/3:`OA2;0](F\,+I\6D#
MP]-IME)HG]E00I;0Z9_930&P.GQ6Z)!'9_9_LZ0HL:QA%"CAO^%%?!+_`*(_
M\+O_``W_`(2_^5%>JT5_%<:E2":C4G%-\S49R5Y::NSU>BU>NA_44J5*5N:G
M3E9)+FA%V2V2NM$NBV/\V3_@Y6\->'?"G_!3;7](\+Z!HOAO2D^"WPFG73-`
MTJQT?3UGFL-5::<66G06UL)I2`991$'D(!=F(!K^A+_@U^^&7PX\7?\`!.;Q
M?JOBOP#X+\3:FG[4GQ+LDU'Q#X6T+6KY+2#P'\)9(;5+O4K"YN%MXY)II$@6
M01))-*ZH&D<G\"/^#G7_`)2C^(?^R(_"'_TWZK7]%_\`P:N?\HU_&7_9UOQ0
M_P#4`^$%?U%QI.:\">$Y*<E)T<A;DI-2;>'>K:=W]_;LC\#X7A!^+/$,'"+@
MJF;VBXIQ5JU.UHVMITTT/H+_`(+S?"3X5^'?^"3G[6^M>'_AKX!T+6+'2?A2
MUEJVC>#O#NEZE9M-\=_A=;3-:WUCIL%U;F6WFEMY3%*AD@EEB?,<CJ?XE_\`
M@AI_RE>_8R_['_Q-_P"JR\<U_=5_P7__`.41/[8/_8(^$G_J_OA57\*O_!#3
M_E*]^QE_V/\`XF_]5EXYI^%4I3\'_$)RE*3MQ*KRDY-)<+X2R3;=DKMVVNV^
MK%XA0A#Q&X14(Q@G_8C:C%13?]N8A7:26MDE?LEV/]39>@^@_E2TB]!]!_*E
MK^5X?!'_``Q_)']`1V7HOR/Y(OB]XI\/>!_^"V5_XQ\6ZQ8>'_#/ACXN^#-<
MU[6]3F6WL-+TK3OACH%S>WMS*WW8X(49R%#.Y`2-7=E4_4OQ,_X+>?$_Q#XJ
MUC3OV6OV>(_%WA+0[EXCXE\8:=XMU[4-6M@SK#J)\.^$)-+/ARVN1&TEK#J.
MKW]W)"5>XBLYQ-:P_G-^WEX$O_BE_P`%1_B)\--,E:"_^(/Q:^%O@NUN`AD%
MM-XF\-^!-&2Y=`5W1VQO/M$F64".-B2`"1_8-\)?A)X`^"GP_P##GPV^''AO
M3?#?A7PUI\%C965E:PQ27+QHJSZEJ<ZHLVHZQJ,H:ZU/5+QI;R_O)9;BYE>1
MR:_N'Q/S7@'AKACP8SGB?A27'&=8OPMX:P.79-B<VQ.4Y/EN`PF!PU?$9EBY
M8*$L3C,7BZN-CAL'AY6PU.&&Q-:;<_9H_P`X_!G)/%#B_B[Q\X?X.XVAX=<.
M8'QBXOS/-<_P>38;.L\S7,\=FF*PV%RC!0QU6EA<#@\%A\N>,QV*A+ZU5GBL
M-AX)TI57#\6/V9O^"WWACQOXUTWX?_M)?#ZS^$EUJE]'I4'CG0]2O;KPII^I
MRRB%;?Q5H^LP)J_ABR$W[F35O[1UBWMG='U*'3K&*ZU"']>OVD/C4/@+\!?B
M-\;K/0HO&">`O#,GB2'01JPT>'6XTFMXEMUUA-/U?[$DJ3^8ERFG7HPH`B(;
M</R"_P""XG[,_@S4/A#H_P"TKH>AV6F>._!_B;1/#?BW5;"SBMY?$?A/Q(TV
MFV3:Y)"J&[O-$UW^R(-+O)]\L=IJ5]:,[1?9DBY_X9_&#6/B_P#\$2/BK)X@
MO+C4-:^'7@OQ3\+KN^N'>1[BS\+ZAHESX<5F?))L_"FKZ#II8N[R&Q,TC%Y&
MQ\#FO`O`?%>2^'OB1P=DV*R')LYX]RK@GC3A&KF6)S"A@,=BL9AY.IE^8SE3
MQD<+BL)/EJ/F@X?7,&Z$,-4C61^EY-XE^)G!&?>*7A+Q[Q!A>),_R'PVSKQ`
MX!XYHY9A<OQ.88+!8&NHT<RRV$9X.6*PF+ASP4J56,Y8''1Q%;&4JE"1^CG[
M`/[;-Q^V_P##_P`9^.YOAQ%\-E\)>,_^$0&EQ^+#XO\`MQ&AZ9K1U!KYO#7A
M@VV1J0MA:"SN`/(,QN<R"*/@_P!M[_@I[\'_`-CN]/@B#3KCXF_%^2T6[;P/
MHVHV^G6/AZ"XC22RG\9Z^]O?_P!C->PN+FRTRTTW4M6N;8Q7,UK8V%W:7TWP
M+_P1S^(-I\)_V'_VL?BA?1B:T^'GBSQ9XTG@)*_:4\-?"K1-7^R@KAMUTUH+
M=`I#L\JA2&(KY7_X)0_`6+]L']J+XF_M`_'&%?'EEX!N[;QKJMKK<8N[#Q#\
M2_'&J:I=:)+J=I,9(+O2]'BTG6M132G0VB7,&APO$VGQO:S>OBO";@+)^-?%
M_B#/\)C:/AOX98C`4<-D&"QV*6+SK-,SP^%6`R>&95ZU7&4Z#Q%6/UFK[=5T
M\5AW&K&E&LX^+@_&_P`2LZ\/O`OA3AK,,%BO%CQ>P^95\7Q1F6`P<L+D&3Y3
MBL6\PSN>5X7#T,!4Q$<+1JRPU-X66&Y,!BE/#U*U2C?VS_A\_P#MG"R_X3<_
MLG>&Q\,R#<IK9\-?%)=/-B6.USXW^UGP\P"X!NUTOR"06\H`[1^G_P"Q#_P4
MW^#W[9%V_@L:;=_#3XNVMD]\_@76]1M=0M-?M8%9[VZ\&:]%%9?VZ+")?M%_
M87.FZ7JUK;>;=QV5UI]K=7T/Z2&TM3";8VUN;<QF$VYAC,)B*;#$8BOEF,I\
MA3;MV?+C'%?R3?\`!5'X%1?L7_M5?#'X\_`B-?`=GX\NKSQWH-AH\?V*P\/?
M$3P/JNE2^)$TFT@,<$&@ZG%K>@ZA+I"HMB9M1UFQBA72WBLX?+X0POA5XSX[
M%<$8'@6GX<\5XK`8W$\(YSEF?9EFN"Q6,P&'J8N669QA,=%1G&KAZ-2I+%TX
M>VE&E4]G.A55.G7]KCG%^-7T?<!@/$/,_$JOXK\%87,\NP?'&0YOPYE>3X_!
M8+,L52P4<UR+&9?.<J<J>+KTJ,,)5J*A3J5J+JPQ%&56>&_KAHKSKX0>/K/X
MJ_"GX;_$W3XQ#9?$'P-X6\9VT`8O]GB\2Z)9:PMN6)8EK?[886^9L,A&3UHK
M^8<1AZV$Q%?"XBG*EB,-6JX>O2E\5*M1G*G5IRMIS0G&47YH_LG!XNAC\)A<
M=A:D:N%QN&H8O#58ZQJT,12C6HU(OK&=.<9+R9Z(2%!)Z"O\YO\`X.'O^"G)
M_;%_:(_X9S^$WB#[7^SK^SEKVI:<;S3;GS=,^)/Q?MQ<Z3XE\8K+"YAO=$\+
M1/>>$/!\R":&9#XFUZRN[G3_`!+9K!_23_P<(_\`!34_L6?LX_\`"BOA1X@^
MQ_M(_M&Z+JFCZ7<Z;<!=5^&_PLE\W2_%GC[?"QN=.UC5RT_A3P/<C[-,NIR:
MWX@TZZ^T^#Y8)?XC?^"8?[#/B7_@H+^V#\./@18PW]IX(%W_`,)G\8_$EF'4
M^&/A3X<NK67Q/=17(1UMM6UMY[+PGX:D>.5%\1:_IDT\36<%TZ?T1X,\*X/*
M\%CO$KB-4Z6`RNABI91&LE_RXC*&+S*,9-<TE[^"P45K.NZ[C[ZH3/QGQ/X@
MQ./Q>$X(R:]7%8VK068NF^M5QEAL"Y;1C*\<3BI-VA2C24GRNK$^A?"__!'7
MXW^)?^"6/BO_`(*.6Z:D+C2/%JZYHOPV6Q_TG5OV>-$2]T?QC\50Q0W?G6/B
M=HM1L[-UM[7_`(0'P[XA\5&:ZMKO2MVU_P`$.O\`@I-=_P#!/G]K#3K3QQK,
M\'[.'QRN-'\$_&6TFD=K'PQ<"ZDA\)?%.*#^&X\$WU_<QZTR*[S^#=6\1(EK
M=:E!I/D?Z76B?#GP/X=^'NF?"C1O"^BV7PYT;PC:>`M-\&I86[^'K;P;8Z1'
MH%KX;&F2H]M+I,>C1)IILYDDBEM`8I0ZLV?\NG_@K]^P!JG_``3U_;+\;_#3
M2K"^_P"%.^-Y+CXB_`K69_-FCN/`6M7]QGPU+>R;_/U?P'JJW7A?4!+*;VYM
M+/2=>N8H8==M-_U7!''>'\4EQ3P?Q32I0AFGUG&91"\(SH9?>'+A:4^6*GC,
MLG"AC*-;6=2;K5.54Z'*OG^*N$Z_`3X?XCR*<I3P,:&'S&;4G&>-2ES8BI%-
MM87'1E4PU6FK1A%4X<SG637^J%9WEKJ%I;7UC<0W=E>00W5I=6\L<]O<VUQ&
MLL%Q;SQ,\4T$T3K)%+&[1R(RNC,I!-FOY:O^#:S_`(*7R?M`_!B7]BGXO^('
MN?C#^S_H$=S\,-3U2Y#7GCGX)6TT%A::6DDKF2[UGX77-Q9:#(@VO+X/OO##
M0Q7#Z/K=XO\`4K7\R\3</8[A;.\?D>8).O@JSC"M%-4\5AYI3PV+I7WIXBC*
M%1*[=.3E2D^>$DOW?(,ZPO$&583-<([4\333G3;3E0K1]VM0G_>I5%*-[+GC
MRU$N6:/\W_\`X.=?^4H_B'_LB/PA_P#3?JM?T7_\&KG_`"C7\9?]G6_%#_U`
M/A!7\Z/_``<Z@G_@J/XA`&2/@A\(B<>G]GZMS7]%W_!JX1_P[8\9<]/VK?BA
MGV_XH#X0=:_H7C5K_B!'"6J_@9!_ZCR_R?W/LS\:X63_`.(M<0NSM[3.-;.W
M\:GU/L3_`(+_`/\`RB)_;!_[!'PD_P#5_?"JOX5?^"&G_*5[]C+_`+'_`,3?
M^JR\<U_=5_P7^_Y1%?M@C_J$?"3_`-7]\*J_S*_AU\1/B#\(O&F@?$?X7>+_
M`!)\/_'WA:YFO?#?C'PEJMYH7B/0KNXL[BPGN=+U;3Y8+RRGEL;RZM))()4=
MH+B:(DJ[`]_@G@99KX9\8Y32JTJ-;,\?G.7TJE5OV=.IC>'\OPT*E113GR0E
M44I<L7)Q3LFSC\4L5'`<<\.X^<)U*>"P>68N<(6YYPPV;8NM*$6[1YI1@U&[
M2NU=I'^S`O0?0?RI:_R9?^'J'_!2O_H^C]JC_P`/3XZ'_N9_E1_P]0_X*5_]
M'T?M4?\`AZ?'?_RYKY)?1TXA22_U@R/1)?#C.BM_SY/H%XU9.DE_8N::67\3
M"^7_`$\\_P"M+_U<?%^_T[3/^"X.F7FJO'':)^T?\%(S)*P2-+BYT+P':V3,
MS,JKMO9K=@6.-P`/!Q7]<".KJ&4Y!SCIV)!Z$CJ#WK_.'_9%;X]_M>:C\-[V
MX\:>(_B%^T!X^D\0:I;>+_%OB:^N_%/B'Q#X/77]0TGS_$VH3S79U?\`L[PS
M9Z7HUU=74<5O/#I\4MS9VD1N(?Z4/AA_P7!NOASX?C^'_P"U'\"_'4/Q7\&I
M_8/B/4?#?]EZ9/J^J6&89;O7?"GB-M!G\,:K+M0ZA:VL]]:277G75G;:?:SP
MV%O^N^-GA+Q-Q+E7A?0X5CA^(<YX8\/,@RC.LDP>*P]+,:&$A1C1P6<T,)BJ
MM"=?`8K%T,?AJDX+VM&="DITY0<YTOY-\`/&GA#@+B;QKI\<5L3PSDG%'BOQ
M5FV1\18S`8VOE&(S"&-J2S'(J^-P6&Q$,/F&%PF)RW%TJ=5JE6IXBKR3A44(
MU_LK_@M%X@T[1_V%?&NFWTRQ7/BOQG\.="T="R@W.HVOBFT\3S0JI(9V72O#
MNI3D*#A8&8X"FOSR_9=\/:AHO_!$K]IW4KR"2*V\7:U\1O$&E2/C;=6-K'X&
M\*2SP_*I\M=3\,ZC:MDM^]MI/F[+\Z?'#XW_`+1?_!7SXP>$/AA\)_AY>^&O
MAEX3U)[RTT^2[FO])T![W%G>>/?B1XCAM+;3[>YMM.,L6DZ5;0&>&&>ZTS15
MUG4M1>2Y_;G]JCX->&?V?_\`@EY\4_@]X15SHW@;X,R:+#<RJJ7&J7O]H6EW
MJ^LW2(S1QWFMZM<7NK7<<9\I+F\E2+$851XL<-/PSX*\,_##.:N&7&?$7BYP
M_P`:9UE-'%4,7+(,MI8K+L%A:&,J8>=2C3Q6*>'P56G&$YQDH8Q*<HTHSGZ]
M3'1\7_$'Q@\8L@P^,_XA_P`+>"'$W`?#^>8G"5\%2XES6M@LRQV-Q&7T\33I
M5JV$PBQ6.I5*DX4YPO@'.G"5:4(_EI_P3L\/:AXI_P""77[?.A:2DTNI7A\?
MR6=O`@>:[FL?A-HFH+8Q(0VY[\6ALU``8F?Y&1L,/1O^#?\`\6Z1%#^TGX(F
MF5-=N)OAOXHLX#M$MWI,$?BS2]0FC7=O:+3KRYTY)VVX0ZI;C/SX'J__``08
MM[>]_9S^-=C=1Q3P7?QBE@GMYHUEAF@E\!^&4EBEC<-')'(A9'1P596*L"#@
M_#/QW^`/Q_\`^"5O[4;?M$?`O0-0\0_`^\U+4)].O([:^OO#]IX5UNZ275OA
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M/#O!F%S.K3^N8W`3QN=YIB\OQ678;+<IP^&Q->>)J36+J5H5(KV=6<*5.BZD
M9U)T?U#QS\7^%?&K@R/A#X/XV7''%''N/R:A6>`P&94L#P_D^!S;`YKB\USC
M%8O!X>&$ITY8*E2G&2<J-*=:K65-PHTZ_P#1W^QCHFH>'/V2/V:M#U:![74M
M-^!_PSM[VVD4I+;7`\):4\EO*C`,LL)?RI58`AU8'FBOI"UMH;.W@M;>-(;>
MVB2""*)%CCBBB4)'''&@"HB(`J(H"JH```%%?RKFF/GFF9YCF=2"IU,QQV+Q
M]2G%WC3GB\14Q$H1?51E4<4^J1_:V1Y9#)<ERC)J=1U:>4Y7E^60JR5I588#
M"4<+&I)='-4E)KNR"YTS3;R037>GV5U*$$8DN;6">0("6"!Y8V8*"S$*#@$D
M@<FEM]-TZT9GM+"RM78;6>VM8(&90<[6:)$++GG!)&>U6P`V&/)QCIQ^7/?W
MZ4ZN)MM<K;:[-NWW;'IV79?<@JG<Z=87A5KRRM+LH&"&YMX;@H&(+!/-1]H8
M@$[<9P,]*N'/;'XC/]12<^H_(_XTEH[K1K9K?[QV3W5RC;Z5I=I*)[73K&VF
M`*B6WM((9`K##`/'&K`$$@@'![U?HI,#K@9]<4VV]6VWW;N))+9)>FA1N-*T
MN[E,]UIUC<S%0IEN+2":0JO"J7DC9B%'`&>.V*GMK.TLHS%9VUO:Q%BYCMH8
MX(RY`!<I&JJ6(506QD@`9X%6**5W:U]%LNB^065[V5]=;*^N^OG97]"*>W@N
M8FAN88IX7QOBF19(GP0PWQN"C88!AN!P0".16?\`V%HG_0&TK_P76G_QFM6B
MFFULVO1M?D%EO97[V1E?V%HG_0&TK_P76G_QFC^PM$_Z`VE?^"ZT_P#C-:F!
MZ#\J7`]!3YY_S2_\"?\`F%EV7W(SXM)TN`HT.G6,+1DLC16L,;(3G)1D0%2<
MG)!&02.A-<)XS^"_P>^(US!>?$+X5?#GQW=VT8BMKKQEX*\-^)[BWB7.V.";
M6]-OI(47<V%C95!8D`$FO2Z3`]!^5:T,5B<+55?#8BOAZ\4U&M0JU*56*:LT
MJE.49I-:-)ZK1G-B<#@<;0GAL9@\+B\-.2E/#XG#T:]"<E9J4Z56$Z<I)I--
MQ;5E9Z&!X<\)^%_!^FP:+X2\.:'X7T>V)-MI/A[2K'1=,MR223#8:=!;6L1)
M))*1+D\G-;<T$-Q&T4\231.,/'(H9&&<X93D$9`X(Q4M%9SJ3J3E5J3G4J3D
MYSJ3DYSG-N[E*<FY2DWJY-MMZMFU.C1HTXT:5*G2HP@J<*5.$84X02LH1IQ2
MC&"6BBDDEHE8KP6EK:Y%M;06X8Y80Q)$"<8R0@4$XXR1G'%+<VUO>0RV]U!%
M<6\T<D,T$R+)#-%*I26*6-P4DCD0E'1U*LI*D$$BIZ*F[O>[O=._6ZV=][JR
ML_(KECR\O+'ELURV7+9[JVUG=W5M3Q:/]F[]GB+5#K<7P'^#<>M-,+AM7C^&
M/@I-4:X#!A.VH+H@NVF#`,)#,7##<&SS7L=O;6]I%';VT,5O!#&D44,*+'%%
M%&H2...-`$CCC0!41`%50%4``"IJ*Z<3C<9C/9_7,7BL5[*/+2^LXBK7]E&R
M7+3]K.7)&R2M&RLDK')@\MR[+_:O`8#!8%UY<];ZGA:&&]M-MMSJ^QIP]I*[
M;YIW=V]=0HHHKE.T,`=!BBBB@`I!GG./;']:**`#`SGOTI:**`$.[MC'OFEH
MHH`0CNN`3W(_P([_`.3B@9QSC/?`('ZDT44`+1110`4444`%%%%`!1110`44
)44`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
